GMP– tag –
-
Automated GMP Facility Launched, Supercharging Scalable Production for Off-the-Shelf Cell Therapies
Company Announcement / Specialized Media International Overview A new, state-of-the-art GMP facility dedicated to commercial-scale allogeneic cell therapy manufacturing has commenced operations. This facility leverages advanced automatio... -
WuXi Advanced Therapies Significantly Expands Cell Therapy Manufacturing Capacity to Meet Surging Client Demand, Reinforcing GMP Capabilities and Process Development
WuXi Advanced Therapies China Overview WuXi Advanced Therapies announced a substantial expansion of its cell therapy manufacturing facilities. This significant investment aims to address the growing demand from clients for complex cell t... -
BioPharma Dive Reports on Cell and Gene Therapy Manufacturing Frontlines: Viral Vector Supply Shortages and CDMO Market Soaring to $9.08 Billion by 2031
BioPharma Dive USA Overview BioPharma Dive analyzes key challenges and commercial opportunities in cell and gene therapy manufacturing, pinpointing viral vector production as the most severe supply constraint. Lonza is significantly expa... -
Century Therapeutics Pivots iPSC Platform to Type 1 Diabetes Beta Cell Therapy, Targeting 2025 IND with Off-the-Shelf Approach
Century Therapeutics USA Overview Century Therapeutics has announced a strategic realignment of its induced pluripotent stem cell (iPSC) platform, now exclusively dedicated to developing beta islet cell therapy for Type 1 Diabetes. The c... -
MIT Engineers Vascular Networks with Mechanical Strain, Overcoming Key Barrier in Artificial Organ Development
Massachusetts Institute of Technology (MIT) USA Overview Researchers at MIT have pioneered a novel method to precisely control the growth of vascular networks by mechanically stretching cells, a critical breakthrough for artificial organ... -
Ultra-Homotypic Targeting: Lanthanide-Modified EVs Boost Cancer Detection Sensitivity by Over 25-Fold
University of Tokyo Japan Overview Researchers at the University of Tokyo, led by Professor Keisuke Goda, have unveiled a groundbreaking 'ultra-homotypic targeting' technology. By engineering extracellular vesicles (EVs) with lanthanide ... -
iPSC-Derived Cell Therapy Pipeline Expands: Hopstem Leads Chinese Market with Neurological and Immunological Disease Applications
BioInformant USA Overview The iPSC-derived cell therapy pipeline is rapidly expanding from disease modeling to clinical applications across cardiovascular, neurological, metabolic, ocular, and oncological diseases. Hopstem Biotechnology ... -
Vector BioMed Proposes Platform to Accelerate CAR-T Therapy Development from Gene Sequence to Clinic-Ready in Under 12 Months
Vector BioMed USA Overview Vector BioMed is advocating for a platform capable of accelerating CAR-T therapy development from gene sequencing to clinic-ready in under 12 months. This platform aims to reduce therapy costs by adopting a tra... -
Cellistic Unveils Specialized CDMO Services for iPSC-Derived Cell Therapies, Expediting Development from Early Stages to GMP
Cellistic Belgium Overview Cellistic is offering specialized Contract Development and Manufacturing Organization (CDMO) services tailored for iPSC-derived cell therapies. Leveraging bioreactor-based, GMP-compliant processes, the company ... -
Porton Advanced’s UC-MSC Cell Bank for Exosome Manufacturing Receives FDA Drug Master File (DMF) Acceptance
Morningstar USA Overview Porton Advanced, a CDMO, announced that its umbilical cord-derived mesenchymal stem cell (UC-MSC) cell bank for exosome manufacturing has received Drug Master File (DMF) acceptance from the U.S. FDA. This accepta...
